UTHR Posts Strong Q4 Revenues, As Well As Expenses

Analysts at Cowen & Co maintain their "outperform" rating on United Therapeutics (NASDAQ: UTHR).

United Therapeutics reported Q4 revenues ahead of expectations, driven by strong Tyvaso revenues. Earnings missed expectations due to higher SG&A and R&D expenses, the analysts say.

“We believe the Tyvaso number ($15.2MM vs our $5.5MME) did not disappoint, and likely came in somewhat ahead of whispers (which we believe were in the $9-12MM range)… Infused Remodulin revenue ($86.4MM vs our $87MME) and Adcirca ($4.3MM vs our $4.0MME) were generally in line with our projections,” the analysts add.

More Analyst Ratings here